BLA 761384 · Abbvie INC
Emrelis
Telisotuzumab Vedotin-Tllv · Single-Dose
NovelBreakthrough therapyAccelerated approvalPriority reviewCDER novel approval, May 14, 2025: To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy
Last checked: Nov 20, 2026Latest source record: May 14, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
May 14, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
10
2 Phase 3, 3 recruiting
FAERS reports
78
34 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 25, 2025.
EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test [see Dosage and Administration ( 2.1 )] , who have received a prior systemic therapy . This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). EMRELIS is a c-Met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. ( 1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )
Mechanism: Telisotuzumab vedotin-tllv is a c-Met-directed antibody drug conjugate (ADC). The antibody is a humanized IgG1κ directed against c-Met, the cell surface receptor for hepatocyte growth factor. The small molecule, MMAE, is a microtubule-disrupting agent, attached to the antibody via a protease cleavable linker. Following binding to c-Met-expressing cells, telisotuzumab vedotin-tllv undergoes internalization and intracellular cleavage of MMAE. MMAE disrupts the microtubule network of actively dividing cells, subsequently inducing cell cycle arrest and apoptotic cell death. Telisotuzumab...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 14, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelMedication GuideLetter
2 products under this application
- EMRELIS · TELISOTUZUMAB VEDOTIN-TLLV 20MG · VIAL, SINGLE-DOSE · Prescription
- EMRELIS · TELISOTUZUMAB VEDOTIN-TLLV 100MG · VIAL, SINGLE-DOSE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Telisotuzumab Vedotin" as an intervention, any sponsor and status, largest first.
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT04928846 · 768 participants (planned) · Start Mar 25, 2022 · Primary completion Dec 2028
Drug: Telisotuzumab Vedotin; Docetaxel · For: Non Small Cell Lung Cancer; c-MET
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 317 sites in all
- Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerActive, not recruiting
AbbVieAbbVie (ABBV)
NCT03539536 · 270 participants · Start Oct 10, 2018 · Primary completion Jul 2026
Drug: Telisotuzumab vedotin · For: Non-small Cell Lung Cancer
Sites: Mobile, Alabama; Phoenix, Arizona; Springdale, Arkansas · 252 sites in all
- A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsActive, not recruiting
AbbVieAbbVie (ABBV)
NCT02099058 · 237 participants · Start Jan 15, 2014 · Primary completion Aug 2026
Drug: Osimertinib; Nivolumab and 3 more · For: Advanced Solid Tumors Cancer
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 36 sites in all
AbbVieAbbVie (ABBV)
NCT06568939 · 150 participants (planned) · Start Jan 20, 2025 · Primary completion Feb 2028
Drug: Telisotuzumab Vedotin · For: Non-Small Cell Lung Cancer; c-MET
Sites: Chandler, Arizona; Little Rock, Arkansas; Los Angeles, California · 83 sites in all
AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
NCT01472016 · 74 participants · Start Oct 6, 2011 · Primary completion Apr 27, 2017
Drug: ABT-700; docetaxel and 4 more · For: Advanced Solid Tumors
Jonsson Comprehensive Cancer CenterAcademic, hospital or other
NCT07323641 · 60 participants (planned) · Start Feb 19, 2026 · Primary completion Feb 1, 2027
Drug: Osimertinib; Telisotuzumab Vedotin · For: Lung Non-Small Cell Carcinoma
Sites: Los Angeles, California
- Lung-MAP S1400K: c-MET PositiveCompleted
SWOG Cancer Research NetworkResearch network
NCT03574753 · 28 participants · Start Mar 16, 2018 · Primary completion Dec 21, 2019
Drug: ABBV-399 · For: Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC V7
Sites: Houston, Texas
AbbVieAbbVie (ABBV)
NCT05513703 · 9 participants · Start Nov 21, 2022 · Primary completion Oct 28, 2024
Drug: Telisotuzumab Vedotin · For: Non Small Cell Lung Cancer
Sites: Los Alamitos, California; Renton, Washington; Clayton, Australia · 29 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use8
- neuropathy peripheral7
- keratitis6
- disease progression5
- interstitial lung disease4
- pneumonia4
- vision blurred4
- death3
- pneumonitis3
- agranulocytosis2
- fatigue2
- ocular toxicity2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 23 |
| 2026 | 50 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
Camidge DR, Bar J, Horinouchi H, et al. · J Clin Oncol 2024 · Clinical Trial, Phase II, Multicenter Study
- First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH, Weekes CD, Nemunaitis J, et al. · J Clin Oncol 2018 · Clinical Trial, Phase I, Multicenter Study
- Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib.
Horinouchi H, Cho BC, Camidge DR, et al. · Ann Oncol 2025 · Clinical Trial, Phase I, Multicenter Study
- Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge DR, Barlesi F, Goldman JW, et al. · J Clin Oncol 2023 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Camidge DR, Morgensztern D, Heist RS, et al. · Clin Cancer Res 2021 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors.
Fujiwara Y, Kenmotsu H, Yamamoto N, et al. · Cancer Med 2021 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.